Ligand Pharmaceuticals Q2 EPS $1.42 Beats $0.64 Estimate, Sales $26.40M Beat $25.73M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals reported Q2 earnings of $1.42 per share, beating the analyst consensus estimate of $0.64 by 121.87%. This is a 37.86% increase from the same period last year. The company also reported quarterly sales of $26.40 million, beating the analyst consensus estimate of $25.73 million by 2.60%. However, this is a 54.02% decrease from the same period last year.
August 08, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ligand Pharmaceuticals reported strong Q2 earnings, beating estimates. However, sales decreased significantly compared to the same period last year.
While Ligand Pharmaceuticals beat earnings estimates, which is generally positive for the stock, the significant decrease in sales compared to the same period last year could be a concern for investors. This mixed result makes the short term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100